Pharmaceutical

Strategies to Increase the Value of Drug Therapy

Strategies to Increase the Value of Drug Therapy

Value is a concept that concerns all healthcare stakeholders.

Fit4D wins MM&M shark-tank challenge

Fit4D wins MM&M shark-tank challenge

Four start-ups presented their business models to pharma executives during the MM&M Transforming Healthcare conference on Thursday in New York City.

Five things for pharma marketers to know: May 1

Five things for pharma marketers to know: May 1

Nexium tops the list of Medicare's spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company

Effective communication requires rethinking the patient experience

Effective communication requires rethinking the patient experience

The patient journey concept needs a reboot, according to executives at the inaugural MM&M Transforming Healthcare conference.

Study shows women view health differently than industry thinks they do

Study shows women view health differently than industry thinks they do

A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.

Five things for pharma marketers to know: Thursday, April 30

Five things for pharma marketers to know: Thursday, April 30

FDA advisory panel recommends Amgen's T-Vec; Teva again makes the case for a merger with Mylan; the FDA approves injection to treat double chins

Valeant adds commercial expertise in Whitaker

Valeant adds commercial expertise in Whitaker

The drugmaker brought in Anne Whitaker, citing her experience in the gastrointestinal space.

Five things for pharma marketers to know: Wednesday, April 29

Five things for pharma marketers to know: Wednesday, April 29

FDA approves generic Abilify; Mylan raises its offer to buy Perrigo; drugmakers are racing to develop drugs for celiac disease.

Bristol-Myers Squibb sales rise, led by Eliquis and Opdivo

Bristol-Myers Squibb sales rise, led by Eliquis and Opdivo

Newly approved Opdivo added $40 million to the quarter's product sales, which rose 8.9% compared to the year-earlier period.

Pfizer reports uptake for cancer-therapy Ibrance

Pfizer reports uptake for cancer-therapy Ibrance

Sales of the new cancer drug topped expectations since its February launch.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.